Linked Life Data

19214143

Source:http://linkedlifedata.com/resource/pubmed/id/19214143

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-4-8
pubmed:abstractText
The two classes of leukotriene modifiers work by inhibiting different portions of the same pathway. We hypothesized that single nucleotide polymorphisms (SNPs) in genes associated with response to montelukast (a cys-leukotriene receptor antagonist) would also be associated with response to zileuton (a 5-lipoxygenase inhibitor). We genotyped 26 SNPs that had previously been interrogated for association with montelukast response in five candidate genes (ABCC1, ALOX5, CYSLTR1, LTA4H, LTC4S) in a population of 577 asthmatics who participated in a clinical trial comparing intermittent and continuous-release zileuton to placebo. After adjusting for age and sex, six SNPs in three genes were associated with longitudinal forced expiratory volume at 1 s in response to zileuton (P values 0.005-0.05). After adjusting for age and sex, six SNPs in three genes were associated with longitudinal forced expiratory volume at 1 s in response to zileuton (P values 0.005-0.05), including two SNPs (ALOX5 rs2115819 and ABCC1 rs119774) that we had previously reported as associated with FEV1 response to montelukast. Thus, the lung function response to zileuton is modulated by several of the loci that also influence montelukast response.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-10075616, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-10369259, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-11359637, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-14529097, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-15696076, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-16250846, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-16293801, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-16647809, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-17460547, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-17507702, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-17718106, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-8598621, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-9062372, http://linkedlifedata.com/resource/pubmed/commentcorrection/19214143-9555757
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1744-6872
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
244-7
pubmed:dateRevised
2011-8-1
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci.
pubmed:affiliation
Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. kelan.tantisira@channing.havard.edu
pubmed:publicationType
Journal Article, Controlled Clinical Trial, Research Support, N.I.H., Extramural